All lobbying filings

CAPITOL COUNSEL LLC

CAPITOL COUNSEL LLC filed a Q3 report for EMERGENT BIOSOLUTIONS on October 18, 2026, reporting $50,000 in lobbying income.

Lobbying for EMERGENT BIOSOLUTIONS · Bio pharmaceutical company.

All filings by CAPITOL COUNSEL LLC · Everything EMERGENT BIOSOLUTIONS has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 18, 2026

Income

$50,000

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Health Issues

Providing guidance on development, acquisition and stockpiling of medical countermeasures for the US government. Reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA). Funding for medical countermeasure enterprise including, SNS, BARDA and Project BioShield; State Opioid Response (SOR) Grant Funding; Substance Abuse and Mental Health Block Grant (SABG) funding. Naloxone access and awareness and opioid prescribing.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.